Mikrobiomik Healthcare

Mikrobiomik is a Spanish biopharmaceutical company specializing in the development of microbiome-derived medicines. The company focuses on transforming Fecal Microbiota Transplantation (FMT) into a standardized, regulated biological drug delivered through oral capsules. Its lead product, MBK-01, is in Phase 3 clinical trials for treating recurrent Clostridioides difficile infections, aiming to be the first such product authorized in Europe. Mikrobiomik also maintains a pipeline targeting liver diseases and multidrug-resistant organisms, supported by its own GMP-certified manufacturing facility. The company's approach leverages the therapeutic potential of the human gut microbiota to address unmet medical needs in infectious and metabolic diseases.